JP2022535006A5 - - Google Patents
Info
- Publication number
- JP2022535006A5 JP2022535006A5 JP2021571011A JP2021571011A JP2022535006A5 JP 2022535006 A5 JP2022535006 A5 JP 2022535006A5 JP 2021571011 A JP2021571011 A JP 2021571011A JP 2021571011 A JP2021571011 A JP 2021571011A JP 2022535006 A5 JP2022535006 A5 JP 2022535006A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- activation
- cancer vaccine
- population
- personalized cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962855718P | 2019-05-31 | 2019-05-31 | |
| US62/855,718 | 2019-05-31 | ||
| PCT/US2020/035307 WO2020243561A1 (en) | 2019-05-31 | 2020-05-29 | Expanded t cell assay |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022535006A JP2022535006A (ja) | 2022-08-04 |
| JP2022535006A5 true JP2022535006A5 (enExample) | 2023-06-06 |
Family
ID=73552967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571011A Pending JP2022535006A (ja) | 2019-05-31 | 2020-05-29 | 増殖ｔ細胞アッセイ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220236253A1 (enExample) |
| EP (1) | EP3976057A4 (enExample) |
| JP (1) | JP2022535006A (enExample) |
| AU (1) | AU2020283030A1 (enExample) |
| CA (1) | CA3142352A1 (enExample) |
| MA (1) | MA56060A (enExample) |
| WO (1) | WO2020243561A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL4023249T3 (pl) | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| MA42543A (fr) | 2015-07-30 | 2018-06-06 | Modernatx Inc | Arn épitope peptidiques concatémériques |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| EP4011451A1 (en) | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| WO2017070601A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (vzv) |
| AU2016341309A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Cancer vaccines |
| AU2016342045A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| PL3386484T3 (pl) | 2015-12-10 | 2022-07-25 | Modernatx, Inc. | Kompozycje i sposoby dostarczania środków terapeutycznych |
| WO2017201342A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding jagged1 for the treatment of alagille syndrome |
| CA3036831A1 (en) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | High purity rna compositions and methods for preparation thereof |
| EP3528821A4 (en) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | HUMAN CYTOMEGALOVIRUS VACCINE |
| MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
| WO2018107088A2 (en) | 2016-12-08 | 2018-06-14 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
| US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
| WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | RESPIRATORY SYNCYTIAL VIRUS Vaccine |
| EP3595676A4 (en) | 2017-03-17 | 2021-05-05 | Modernatx, Inc. | RNA VACCINES AGAINST ZOONOSES |
| US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| EP3668979A4 (en) | 2017-08-18 | 2021-06-02 | Modernatx, Inc. | METHOD OF HPLC ANALYSIS |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| MA49914A (fr) | 2017-08-18 | 2021-04-21 | Modernatx Inc | Procédés analytiques par hplc |
| EP3675817A1 (en) | 2017-08-31 | 2020-07-08 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| WO2019055807A1 (en) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | RNA VACCINES AGAINST ZIKA VIRUS |
| EP3746090A4 (en) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | RSV RNA Vaccines |
| CA3113025A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| WO2020061295A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| AU2020224103A1 (en) | 2019-02-20 | 2021-09-16 | Modernatx, Inc. | Rna polymerase variants for co-transcriptional capping |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| CN113874502A (zh) | 2019-03-11 | 2021-12-31 | 摩登纳特斯有限公司 | 补料分批体外转录方法 |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| IL297419B2 (en) | 2020-04-22 | 2025-02-01 | BioNTech SE | Coronavirus vaccine |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP4274607A1 (en) | 2021-01-11 | 2023-11-15 | ModernaTX, Inc. | Seasonal rna influenza virus vaccines |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| EP4648793A1 (en) | 2023-01-11 | 2025-11-19 | ModernaTX, Inc. | Personalized cancer vaccines |
| WO2024231621A1 (fr) * | 2023-05-05 | 2024-11-14 | Centre National De La Recherche Scientifique | Acide nucleique synthetique et ses utilisations therapeutiques |
| WO2025083147A1 (en) * | 2023-10-17 | 2025-04-24 | Transimmune Ag | Methods for analyzing immune responses and antigen profiling |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103502439B (zh) * | 2011-04-13 | 2016-10-12 | 因缪尼卡姆股份公司 | 用于抗原特异性t细胞增殖的方法 |
| US20180171294A1 (en) * | 2015-03-26 | 2018-06-21 | The Trustees Of The University Of Pennsylvania | In vitro artificial lymph node method for sensitization and expansion of t cells for therapy and epitope mapping |
| US11365392B2 (en) * | 2016-08-05 | 2022-06-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Ex vivo generation of MHCII restricted CD4+ FOXP3+ regulatory T cells and therapeutic uses thereof |
| US20190351040A1 (en) * | 2017-02-01 | 2019-11-21 | Modernatx, Inc. | Rna cancer vaccines |
| WO2019196088A1 (en) * | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Methods of obtaining tumor-specific t cell receptors |
-
2020
- 2020-05-29 US US17/615,202 patent/US20220236253A1/en active Pending
- 2020-05-29 CA CA3142352A patent/CA3142352A1/en active Pending
- 2020-05-29 EP EP20813362.9A patent/EP3976057A4/en active Pending
- 2020-05-29 MA MA056060A patent/MA56060A/fr unknown
- 2020-05-29 AU AU2020283030A patent/AU2020283030A1/en not_active Abandoned
- 2020-05-29 JP JP2021571011A patent/JP2022535006A/ja active Pending
- 2020-05-29 WO PCT/US2020/035307 patent/WO2020243561A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022535006A5 (enExample) | ||
| WO2006065495A3 (en) | Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens | |
| ES2619833T3 (es) | Linaje de células dendríticas plasmacitoides usado en terapia celular activa o adoptiva. | |
| Pan et al. | Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells | |
| RU2008122550A (ru) | Композиции и способы индуцирования активации незрелых моноцитарных дендритных клеток | |
| AR107278A1 (es) | Procedimientos de producción de linfocitos t y linfocitos t producidos por ellos | |
| JP2007537732A5 (enExample) | ||
| CN110747166A (zh) | 一种外周血t细胞的体外扩增培养方法 | |
| JP2022541523A5 (enExample) | ||
| CN103667189B (zh) | 用于治疗肺癌的cd8毒性t淋巴细胞及其制备方法 | |
| CN113943704B (zh) | 一种肿瘤新生抗原特异性t细胞的制备方法 | |
| CN112779217B (zh) | 一种高记忆表型肿瘤浸润t淋巴细胞的培养方法 | |
| CN104395461B (zh) | 得到单核细胞或nk细胞的方法 | |
| CN110484504B (zh) | 一种用于免疫治疗原发性肝细胞肝癌的细胞亚群及其制备方法 | |
| Hansen et al. | Autocrine CCL19 blocks dendritic cell migration toward weak gradients of CCL21 | |
| JP2015509382A (ja) | 組織構築体およびその使用 | |
| Berk et al. | Lymphocyte-polarized dendritic cells are highly effective in inducing tumor-specific CTLs | |
| Son et al. | Enhanced maturation and function of dendritic cells using hydrogel coated plate and antigen electroporation | |
| Kimura et al. | Selective expansion and differentiation of antigen-specific CD4+ T-helper cells by engineered extracellular vesicles | |
| Yu et al. | Biomimetic vesicles engineered from modified tumour cells act as personalized vaccines for post-surgical cancer immunotherapy | |
| CN115851869A (zh) | 一种肿瘤抗原免疫原性的体外评估方法及其应用 | |
| Najafi et al. | Organoid-Immune Co-Cultures: A Next-Generation approach to disease modeling | |
| Valdez et al. | Efficient enrichment of functional ILC subsets from human PBMC by immunomagnetic selection | |
| Russell et al. | USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristics | |
| CN105219727A (zh) | 一种用于激活结直肠癌特异性免疫反应的试剂盒 |